Summer 2027
Technology Intern
Posted on 8/10/2026
McKesson
10,001+ employees
Pharmaceuticals and medical supplies distributor.
Compensation Overview
$16.50 - $27.50/hr
No H1B Sponsorship
Columbus, OH, USA
Hybrid
Hybrid role in Columbus, Ohio.
Bachelor's
 Software Engineering (1) |
|---|
Get referred to McKesson
See people who can refer or advise you
- Must be currently enrolled in a bachelor's degree program such as Computer Engineering, Computer Science, Electrical Engineering, or Electronics Engineering and scheduled to graduate in Spring 2028 or sooner.
- Have working knowledge of software engineering architecture, best practices, platforms, and technology stacks, with willingness to learn across multiple technology stacks.
- Have a minimum GPA of 3.0.
- Have strong planning and organizational skills.
- Be able to communicate technical concepts to non-technical audiences.
- Assist in the analysis, design, documentation, engineering, and automation of solutions built for internal and external partners.
- Work primarily embedded with a technology team aligned to the intern's skillset and career goals.
- Gain practical experience across technology areas including Software Development, Site Reliability, Cloud and Database Engineering, and Product Technology.
- Demonstrate a track record of quickly learning new technology stacks.
- Share and receive feedback and knowledge to support continuous improvement.
- Work closely with cross-functional teams to find solutions collaboratively.
- Explain technical choices effectively during problem-solving.
- Contribute in a fast-paced environment as a self-starter with interpersonal and creative problem-solving skills.
McKesson is a global healthcare distributor and services provider. It buys pharmaceuticals and medical products from manufacturers and distributes them to pharmacies, hospitals, and other healthcare facilities, acting as an intermediary in the supply chain. Its core work includes logistics and supply chain management, ensuring medicines and medical supplies reach customers on time and safely. McKesson also offers technology solutions to help healthcare providers manage operations and procurement. Compared with competitors, it leverages a very large-scale network and integrated services—combining distribution, logistics, and technology—across providers, pharmacies, and manufacturers. The company aims to support the healthcare system by keeping essential medical supplies available and helping healthcare facilities run more efficiently, ultimately improving patient care.
Company Size
10,001+
Company Stage
IPO
Headquarters
Irving, Texas
Founded
1833
Get referred to McKesson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Fiscal 2026 revenue hit $403.4 billion, up 12%, with EPS up 18%.
- Moore's $179 million hub opens automation-driven capacity for Oklahoma and Texas.
- Board added $5 billion buybacks and raised the dividend to $0.94.
What critics are saying
- Medical-Surgical separation targets 2027, and Apollo financing increases execution complexity.
- Opioid settlement overhang keeps legal scrutiny active through 2026 and beyond.
- GLP-1 revenue concentration ties growth to Novo Nordisk and Eli Lilly pricing.
What makes McKesson unique
- McKesson moves one-third of North American pharmaceuticals through unmatched distribution scale.
- PRISM Vision and Core Ventures deepen McKesson's specialty oncology network.
- Automated hubs like Moore add cold-chain capacity and regional delivery resilience.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Performance Bonus
401(k) Company Match
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -1%2 year growth
↓ -1%Global Healthcare Fraud Detection Market to reach $9.1 billion by 2030, driven by AI adoption and regulatory pressure. "According to BCC Research, the global healthcare fraud detection market is projected to grow from $4.4 billion in 2024 to $9.1 billion by 2030, at a CAGR of 12.7%, driven by rising healthcare fraud cases, advances in AI and analytics, expanding cloud-based solutions and increasing adoption across global healthcare systems." Boston, Aug. 03, 2026 (GLOBE NEWSWIRE) - The global healthcare fraud detection market is poised for substantial growth, expanding from $4.4 billion in 2024 to $9.1 billion by 2030, representing a compound annual growth rate of 12.7%, according to a new report from BCC Research titled Global Healthcare Fraud Detection Market. BCC Research is a leading provider of market intelligence and advisory services for emerging technology markets. Key Findings * Market expansion accelerating: The healthcare fraud detection market will more than double over the forecast period, driven by escalating fraud losses and intensifying regulatory enforcement across global healthcare systems * North America dominates: The region commands 46.8% of the global market, reflecting advanced healthcare digitization, stringent regulatory frameworks, and sophisticated fraud detection infrastructure * AI transformation: Accelerated adoption of artificial intelligence, machine learning, and predictive analytics technologies is revolutionizing fraud detection capabilities, enabling real-time monitoring and prevention * Digital infrastructure boom: Widespread implementation of electronic health records and digital claims processing systems is creating vast datasets that power advanced fraud detection algorithms * Emerging market opportunity: Growing digitization of healthcare systems and expansion of insurance coverage in developing markets presents significant growth potential for fraud detection vendors * Competitive landscape consolidation: Established technology leaders including McKesson Corp., IBM Corp., SAS Institute Inc., and Optum Inc. are competing alongside specialized providers like FICO and emerging cloud-native platforms Market Drivers The healthcare fraud detection market is experiencing unprecedented growth driven by the mounting economic impact of healthcare fraud, which costs the industry hundreds of billions annually. Regulatory bodies worldwide are implementing stricter oversight and enforcement mechanisms, compelling healthcare organizations and insurers to invest heavily in sophisticated detection systems. The convergence of artificial intelligence and healthcare digitization is creating a perfect storm for market expansion, as AI-powered systems can analyze vast datasets in real-time to identify suspicious patterns and anomalies that traditional rule-based systems might miss. The shift toward value-based care models and increased transparency requirements are further amplifying demand for comprehensive fraud detection solutions. As healthcare systems become increasingly digital and interconnected, the attack surface for fraudulent activities expands, necessitating more advanced and integrated detection capabilities. Investment Considerations The healthcare fraud detection market presents compelling investment opportunities, particularly for companies developing AI-driven platforms and cloud-based solutions that can scale rapidly across different healthcare ecosystems. The market's defensive characteristics-driven by regulatory compliance rather than discretionary spending-provide resilience during economic downturns. However, investors should consider data privacy regulations and integration complexities as potential headwinds that could slow adoption. Companies with strong partnerships in the healthcare ecosystem and proven regulatory compliance track records, such as Optum and McKesson, appear best positioned to capture market share, while pure-play technology providers like FICO offer more concentrated exposure to the fraud detection opportunity. About the Report The report provides comprehensive market sizing, detailed segmentation analysis, competitive intelligence, and strategic forecasts for the global healthcare fraud detection market through 2030. Global Healthcare Fraud Detection Market includes in-depth analysis of technology trends, regulatory impacts, and investment opportunities across all major geographic regions. About BCC Research BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts assess growth trends, identify and evaluate new and changing market opportunities, and provide critical information and innovative decision support tools to help inform the strategic decision-making process. For media inquiries, email [email protected] or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. BCC Research LLC 50 Milk St., Ste. 16, Boston, MA 02109 [email protected] | +1 781-489-7301 www.bccresearch.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
McKesson Corporation announced a quarterly dividend of $0.94 per share, payable on 1 October 2026 to shareholders of record as of 1 September 2026. The healthcare distributor recently increased its share repurchase authorisation by $5 billion, signalling management confidence in the company's earnings power. McKesson's investment case centres on its position as a scale healthcare distributor benefiting from growing drug demand, whilst managing tight margins and regulatory pressure. The company projects $499.3 billion in revenue and $6.1 billion in earnings by 2029, requiring 7.4% annual revenue growth. Simply Wall St community members estimate McKesson's fair value between $827.49 and $2,283.03 per share. The company continues focusing on capital allocation whilst investing in automation and analytics to improve efficiency in the pharmaceutical supply chain.
RH strengthens leadership team with 2 appointments. Thomas Lester// Retail Editor//July 23, 2026 Corte Madera, Calif. - Upscale home furnishings retailer RH announced a pair of appointments to its senior leadership team. In her new role, Pilon will lead the company's gallery, hospitality, interior design, trade, contract, delight, people and optimization teams across every touchpoint of the Corte Madera, Calif.-based retailer's brand globally. Pilon has been with RH for 18 years and has held key leadership positions across the organization, including field leader of its Northern and Southern California galleries, senior vice president of delight and customer service operations, and most recently served as the company's chief people officer. "Over the past 18 years Sandy has been an important partner and leader of RH's transformation into the leading luxury home brand in the world," said Gary Friedman, chairman and CEO. "Her exceptional leadership and passionate advocacy of our values and beliefs give me great confidence in Sandy's ability to build and lead a team capable of building one of the most admired brands in the world." "I am deeply grateful for the trust Gary and our leadership team have placed in me," Pilon said. "Having spent the last 18 years growing alongside this extraordinary organization, it is an incredible honor to step into this role. I believe the greatest luxury we can offer is an exceptional experience - one that reflects our values in every interaction, inspires our people to do their life's best work, and creates lasting relationships with teams and customers around the world. I couldn't be more excited for what we will build." As chief legal and compliance officer, Hassanein will oversee all areas of the company's legal and compliance functions, including product safety and vendor compliance. He will report to Friedman. Prior to joining RH, Hassanein spent more than 10 years at McKesson Corp., one of the largest healthcare companies in the world, where he was a member of the chief legal officer's leadership team with responsibilities spanning a wide range of areas, including litigation, regulatory, compliance, government relations, supply chain and technology. "We are thrilled to welcome Ryan to Team RH," Friedman said. "Ryan's leadership experience extends well beyond the traditional scope of a legal role based on the range of his contributions at McKesson, one of the largest and most sophisticated companies in the world from a legal and compliance perspective. We believe Ryan is an outstanding addition to our executive leadership team as we continue to optimize our business as part of our growth and international expansion." Added Hassanein, "I am honored to join Gary and Team RH in the quest to build one of the most admired brands in the world and excited to participate in such an extraordinary effort. I look forward to making a meaningful contribution as RH continues to scale its business and strengthen its operational capabilities."
RH announces new staff promotion & appointment. RH announced the promotion of Sandy Pilon to Chief Customer Experience & Values Officer, and the appointment of Ryan Hassanein as Chief Legal & Compliance Officer. In her new role, Sandy will lead the Company's Gallery, Hospitality, Interior Design, Trade, Contract, Delight, People and Optimization teams across every touchpoint of the RH Brand globally. Sandy has been a member of Team RH for 18 years and has held key leadership positions across the organization, including Field Leader of its Northern and Southern California Galleries, Senior Vice President of Delight and Customer Service Operations, and most recently served as the Company's Chief People Officer. Gary Friedman, RH chairman and CEO, commented, "Over the past 18 years Sandy has been an important partner and leader of RH's transformation into the leading luxury home brand in the world. Her exceptional leadership and passionate advocacy of our Values and Beliefs give me great confidence in Sandy's ability to build and lead a team capable of building one of the most admired brands in the world." Sandy said, "I am deeply grateful for the trust Gary and our Leadership Team have placed in me. Having spent the last 18 years growing alongside this extraordinary organization, it is an incredible honor to step into this role. I believe the greatest luxury we can offer is an exceptional experience - one that reflects our values in every interaction, inspires our people to do their life's best work, and creates lasting relationships with teams and customers around the world. I couldn't be more excited for what we will build." Ryan Hassanein will oversee all areas of the Company's legal and compliance functions, including product safety and vendor compliance. Prior to joining RH, Mr. Hassanein spent over ten years at McKesson Corporation, one of the largest healthcare companies in the world, where he was a member of the Chief Legal Officer's leadership team with responsibilities spanning a wide range of areas, including litigation, regulatory, compliance, government relations, supply chain and technology. Mr. Hassanein will report to RH Chairman and Chief Executive Officer Gary Friedman and serve as a member of the Company's Executive Leadership Team. Friedman commented, "We are thrilled to welcome Ryan to Team RH. Ryan's leadership experience extends well beyond the traditional scope of a legal role based on the range of his contributions at McKesson, one of the largest and most sophisticated companies in the world from a legal and compliance perspective. We believe Ryan is an outstanding addition to our Executive Leadership Team as we continue to optimize our business as part of our growth and international expansion." Mr. Hassanein said, "I am honored to join Gary and Team RH in the quest to build one of the most admired brands in the world and excited to participate in such an extraordinary effort. I look forward to making a meaningful contribution as RH continues to scale its business and strengthen its operational capabilities."
McKesson Corporation, the leading pharmaceutical distributor in North America, has demonstrated strong financial performance. In fiscal 2026, revenues reached $403.4 billion, up 12% from the previous year, whilst adjusted earnings per share rose 18% year-over-year to $39.11. The company operates through four segments, with North American Pharmaceutical generating $336.7 billion in revenue. Specialty pharmaceuticals and GLP-1 medications for diabetes and obesity are key growth drivers, with GLP-1 revenues alone reaching nearly $41 billion in FY25. McKesson is streamlining operations by selling its Canadian business, exiting Norway, and planning to spin off its Medical-Surgical unit. Simultaneously, it's expanding its US Oncology Network through acquisitions of PRISM Vision and Core Ventures, aiming to increase exposure to higher-margin specialty and oncology services.